Literature DB >> 10652239

Regulation of genes for inducible nitric oxide synthase and urea cycle enzymes in rat liver in endotoxin shock.

S Tabuchi1, T Gotoh, K Miyanaka, K Tomita, M Mori.   

Abstract

Arginine is an intermediate of the urea cycle in the liver. It is synthesized by the first four enzymes of the cycle, carbamylphosphate synthetase I, ornithine transcarbamylase, argininosuccinate synthetase, and argininosuccinate lyase, and is hydrolyzed to urea and ornithine by arginase I, forming the cycle. In endotoxemia shock, inducible nitric oxide (NO) synthase (iNOS) is induced in hepatocytes and arginine is utilized for NO production. Regulation of the genes for iNOS and the urea cycle enzymes was studied using lipopolysaccharide (LPS)-treated rat livers. When rats were injected intraperitoneally with LPS, iNOS mRNA was markedly induced. Cationic amino acid transporter-2 and C/EBPbeta mRNAs were also highly increased. In contrast, mRNAs for all the urea cycle enzymes except ornithine transcarbamylase were gradually decreased and reached 16-28% of controls at 12 h. However, all these enzymes remained unchanged at protein level up to 24 h. In light of these results, we suggest that synthesis of urea cycle enzymes is downregulated and that the protein synthetic capacity is directed to synthesis of proteins required for defense against endotoxemia. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652239     DOI: 10.1006/bbrc.2000.2105

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  In vivo measurement of nitric oxide production in porcine gut, liver and muscle during hyperdynamic endotoxaemia.

Authors:  Maaike J Bruins; Wouter H Lamers; Alfred J Meijer; Peter B Soeters; Nicolaas E P Deutz
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Differential liver protein expression during schistosomiasis.

Authors:  Marina Harvie; Thomas William Jordan; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

3.  A proteomic analysis of liver mitochondria during acute endotoxemia.

Authors:  Elliott D Crouser; Mark W Julian; Jennifer E Huff; David V Mandich; Kari B Green-Church
Journal:  Intensive Care Med       Date:  2006-06-02       Impact factor: 17.440

4.  Inhibition of inducible nitric oxide synthase prevents hepatic, but not pulmonary, injury following ischemia-reperfusion of rat liver.

Authors:  Yuji Takamatsu; Kazuo Shimada; Koji Yamaguchi; Syoji Kuroki; Kazuo Chijiiwa; Masao Tanaka
Journal:  Dig Dis Sci       Date:  2006-03       Impact factor: 3.199

5.  Isotopic study of L-Arginine kinetics in the lung during pseudomonas sepsis in an ovine model.

Authors:  Hongzhi Xu; Davin Watson; Yong-Ming Yu; Daniel L Traber; Stefani Fischer; Joan Nichols; Donald Deyo; Lillian L Traber; Joaquin Cortiella
Journal:  Int J Burns Trauma       Date:  2014-02-22

6.  Isotopic study of L-Arginine kinetics in the lung during pseudomonas sepsis in an ovine model.

Authors:  Hongzhi Xu; Davin Watson; Yong-Ming Yu; Daniel L Traber; Stefani Fischer; Joan Nichols; Donald Deyo; Lillian L Traber; Joaquin Cortiella
Journal:  Int J Burns Trauma       Date:  2013-11-01

7.  Effect of bradykinin on nitric oxide production, urea synthesis and viability of rat hepatocyte cultures.

Authors:  Settimio Sesti; Guglielmo Martino; Sergio Mazzulla; Rosa Chimenti
Journal:  BMC Physiol       Date:  2005-01-25

Review 8.  Arginine and citrulline and the immune response in sepsis.

Authors:  Karolina A P Wijnands; Tessy M R Castermans; Merel P J Hommen; Dennis M Meesters; Martijn Poeze
Journal:  Nutrients       Date:  2015-02-18       Impact factor: 5.717

9.  Adalimumab ameliorates abdominal aorta cross clamping which induced liver injury in rats.

Authors:  Erkan Cure; Medine Cumhur Cure; Levent Tumkaya; Yildiray Kalkan; Ibrahim Aydin; Aynur Kirbas; Arif Yilmaz; Suleyman Yuce; Ahmet Fikret Yücel
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.